• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Potential Strategies to Reduce Blood Pressure in Treatment-Resistant Hypertension Using Food and Drug Administration-Approved Nanodrug Delivery Platforms.利用美国食品药品监督管理局批准的纳米药物递送平台降低顽固性高血压血压的潜在策略。
Hypertension. 2019 Feb;73(2):250-257. doi: 10.1161/HYPERTENSIONAHA.118.12005.
2
Amlodipine approved for hypertension, angina therapy.氨氯地平获批用于高血压、心绞痛治疗。
Clin Pharm. 1993 Feb;12(2):93.
3
Trandolapril approved for marketing.群多普利获准上市。
Am J Health Syst Pharm. 1996 Jul 15;53(14):1649. doi: 10.1093/ajhp/53.14.1649.
4
The FDA's decisions regarding new indications for approved drugs. Where's the evidence?美国食品药品监督管理局关于已批准药物新适应症的决定。证据何在？
JAMA. 1996;276(16):1342-3. doi: 10.1001/jama.276.16.1342.
5
Drug markers questioned.药物标志物受到质疑。
Nature. 2008 Apr 3;452(7187):510-1. doi: 10.1038/452510a.
6
Experience with an innovative new Food and Drug Administration pathway for first-in-human studies: carotid baroreceptor amplification for resistant hypertension.食品药品监督管理局一项针对首次人体研究的创新新途径的经验：用于顽固性高血压的颈动脉压力感受器放大。
JACC Cardiovasc Interv. 2014 Nov;7(11):1328-30. doi: 10.1016/j.jcin.2014.07.009. Epub 2014 Oct 15.
7
U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.美国食品药品监督管理局批准安必素（两性霉素B脂质体）用于治疗内脏利什曼病。
Clin Infect Dis. 1999 Jan;28(1):42-8; discussion 49-51. doi: 10.1086/515085.
8
The AJH visits FDA.《美国医院杂志》访问美国食品药品监督管理局。
Am J Hypertens. 2012 Aug;25(8):835-6. doi: 10.1038/ajh.2012.89.
9
FDA proposes plan for phasing out CFC-containing drug products.美国食品药品监督管理局提议逐步淘汰含氟氯化碳药品的计划。
Am J Health Syst Pharm. 1997 May 1;54(9):1021-2. doi: 10.1093/ajhp/54.9.1021.
10
Liposomal formulation of amphotericin B approved for marketing.两性霉素B脂质体制剂已获批准上市。
Am J Health Syst Pharm. 1997 Nov 1;54(21):2426, 2433. doi: 10.1093/ajhp/54.21.2426.

引用本文的文献

1
A Comprehensive Review on Nanoparticles as Drug Delivery System and Their Role for Management of Hypertension.关于纳米颗粒作为药物递送系统及其在高血压管理中的作用的综合综述。
Curr Pharm Biotechnol. 2025;26(2):169-185. doi: 10.2174/0113892010291414240322112508.
2
Nanoparticle-Based Therapies in Hypertension.基于纳米颗粒的高血压治疗方法。
Hypertension. 2023 Dec;80(12):2506-2514. doi: 10.1161/HYPERTENSIONAHA.123.19523. Epub 2023 Sep 28.
3
Microneedles and Their Application in Transdermal Delivery of Antihypertensive Drugs-A Review.微针及其在抗高血压药物经皮给药中的应用——综述
Pharmaceutics. 2023 Jul 27;15(8):2029. doi: 10.3390/pharmaceutics15082029.
4
The link between immunity and hypertension in the kidney and heart.肾脏和心脏中免疫与高血压之间的联系。
Front Cardiovasc Med. 2023 Mar 9;10:1129384. doi: 10.3389/fcvm.2023.1129384. eCollection 2023.
5
Neurogenic Hypertension, the Blood-Brain Barrier, and the Potential Role of Targeted Nanotherapeutics.神经原性高血压、血脑屏障与靶向纳米疗法的潜在作用。
Int J Mol Sci. 2023 Jan 22;24(3):2213. doi: 10.3390/ijms24032213.
6
Theranostic Nanomedicines for the Treatment of Cardiovascular and Related Diseases: Current Strategies and Future Perspectives.用于治疗心血管及相关疾病的诊疗纳米药物：当前策略与未来展望
Pharmaceuticals (Basel). 2022 Apr 1;15(4):441. doi: 10.3390/ph15040441.
7
Role of Organic and Inorganic Nanoparticles in the Drug Delivery System for Hypertension Treatment: A Systematic Review.有机和无机纳米颗粒在高血压治疗药物传递系统中的作用：系统评价。
Curr Cardiol Rev. 2022;18(1):e110621194025. doi: 10.2174/1573403X17666210611115823.
8
Redox Switches Controlling Nitric Oxide Signaling in the Resistance Vasculature and Implications for Blood Pressure Regulation: Mid-Career Award for Research Excellence 2020.调控阻力血管中一氧化氮信号的氧化还原开关及其对血压调节的影响：2020 年研究卓越中期职业奖。
Hypertension. 2021 Sep;78(4):912-926. doi: 10.1161/HYPERTENSIONAHA.121.16493. Epub 2021 Aug 23.
9
Extracellular Vesicles in Cardiovascular Diseases: Alternative Biomarker Sources, Therapeutic Agents, and Drug Delivery Carriers.细胞外囊泡在心血管疾病中的作用：替代生物标志物来源、治疗剂和药物递送载体。
Int J Mol Sci. 2019 Jul 3;20(13):3272. doi: 10.3390/ijms20133272.

本文引用的文献

1
Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization.纳米颗粒纳米药物临床转化的当前趋势与挑战：转化发展与商业化途径
Front Pharmacol. 2018 Jul 17;9:790. doi: 10.3389/fphar.2018.00790. eCollection 2018.
2
Enhanced physicochemical stability and efficacy of angiotensin I-converting enzyme (ACE) - inhibitory biopeptides by chitosan nanoparticles optimized using Box-Behnken design.壳聚糖纳米粒优化的血管紧张素转化酶（ACE）抑制性生物活性肽的理化稳定性和功效增强。
Sci Rep. 2018 Jul 10;8(1):10411. doi: 10.1038/s41598-018-28659-5.
3
Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?纳米药物及其后续版本的监管挑战：通用或类似方法？
Adv Drug Deliv Rev. 2018 Jun;131:122-131. doi: 10.1016/j.addr.2018.06.024. Epub 2018 Jun 30.
4
Diagnosis and management of resistant hypertension: state of the art.耐药性高血压的诊断和治疗：最新进展。
Nat Rev Nephrol. 2018 Jul;14(7):428-441. doi: 10.1038/s41581-018-0006-6.
5
Polylactic Acid/Chitosan Nanoparticles Loading Nifedipine: Characterization Findings and Investigation in Animal.负载硝苯地平的聚乳酸/壳聚糖纳米颗粒：表征结果及动物实验研究
J Nanosci Nanotechnol. 2018 Apr 1;18(4):2294-2303. doi: 10.1166/jnn.2018.14537.
6
Progress in Nanomedicine: Approved and Investigational Nanodrugs.纳米医学进展：已获批和正在研究的纳米药物
P T. 2017 Dec;42(12):742-755.
7
Decoding resistant hypertension signalling pathways.解析难治性高血压的信号通路
Clin Sci (Lond). 2017 Nov 28;131(23):2813-2834. doi: 10.1042/CS20171398. Print 2017 Dec 1.
8
Progress in brain targeting drug delivery system by nasal route.经鼻给药脑靶向给药系统的研究进展。
J Control Release. 2017 Dec 28;268:364-389. doi: 10.1016/j.jconrel.2017.09.001. Epub 2017 Sep 6.
9
Resistant Hypertension: Mechanisms and Treatment.顽固性高血压：机制与治疗
Curr Hypertens Rep. 2017 Jul;19(7):56. doi: 10.1007/s11906-017-0754-x.
10
Rapamycin nanoparticles localize in diseased lung vasculature and prevent pulmonary arterial hypertension.雷帕霉素纳米颗粒定位于患病的肺血管系统并预防肺动脉高压。
Int J Pharm. 2017 May 30;524(1-2):257-267. doi: 10.1016/j.ijpharm.2017.03.069. Epub 2017 Mar 28.

Potential Strategies to Reduce Blood Pressure in Treatment-Resistant Hypertension Using Food and Drug Administration-Approved Nanodrug Delivery Platforms.

作者信息

Fancher Ibra S, Rubinstein Israel, Levitan Irena

机构信息

From the Division of Pulmonary, Critical Care, Sleep, and Allergy Medicine, Department of Medicine, University of Illinois at Chicago (I.S.F., I.R., I.L.).

Jesse Brown VA Medical Center, Chicago, Illinois (I.R.).

出版信息

Hypertension. 2019 Feb;73(2):250-257. doi: 10.1161/HYPERTENSIONAHA.118.12005.

DOI:10.1161/HYPERTENSIONAHA.118.12005
PMID:30624988
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6338082/
Abstract
摘要